dr mark hyman glp 1 Dr. on GLP‑1 drugs facing multiple lawsuits Mark Hyman, MD | Physician

With over 15 years of research experience in weight loss and metabolic management , the team is dedicated to exploring the most advanced treatment methods, resulting in this revolutionary product

For Novo Nordisk, Wegovy holds 16.5% of the market, Rybelsus 6.0% , Saxenda 1.6% , and Victoza 1.1%

Final thoughts If youre reading this because youre considering GLP-1 therapy, or already using it and want a more comprehensive approach, here are key take-aways: GLP-1s can be powerful tools for glycemic control and weight/metabolic healthbut they carry side-effects and nutrient risks

News provided by Amble Health May 06, 2026, 07:07 ET Leveling the Starting Line: The First Telehealth Platform Bringing Affordable Access to Weight Loss Treatments to America's Disenfranchised Populations CORTLAND, Ohio, May 6, 2026 /PRNewswire/ -- Amble Health, a healthcare platform built to close the wealth gap in metabolic care, today announced the launch of the Amble Cares Program